Folate fluorescein isothiocyanate conjugate

Drug Profile

Folate fluorescein isothiocyanate conjugate

Alternative Names: EC-17; Folate receptor-alpha-targeted fluorescent agent - OnTarget Laboratories; Folate receptor-alpha-targeted imaging agent - OnTarget Laboratories; Folate-5-fluorescein isothiocyanate; Folate-FITC conjugate; Folate-fluorescein isothiocyanate; OTL-0038; OTL-38

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator Endocyte; Purdue University
  • Developer Centre for Human Drug Research; Indiana University School of Medicine; Leiden University Medical Center; On Target Laboratories; Purdue University; University of Pennsylvania
  • Class Cancer vaccines; Fluoresceins; Haptens; Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I Breast cancer; Lung cancer; Pituitary cancer; Primary hyperparathyroidism; Renal cell carcinoma

Most Recent Events

  • 05 Aug 2016 On Target Laboratories plans a phase II trial for Lung cancer (Diagnosis) in USA (NCT02872701)
  • 01 Dec 2015 Clinical trials in Renal cell carcinoma (Diagnosis) in USA (IV) (NCT02645409)
  • 01 Oct 2015 Phase-I clinical trials in Pituitary cancer (Diagnosis) in USA (IV) (NCT02629549)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top